Can-Fite heads to second trial for arthritis drug
The company completed the previous trial for its CF-101drug in mid-2007.
Gali Weinreb 24 Feb 08 17:02
Can-Fite BioPharma Ltd. (TASE:CFBI) is preparing to conduct a second Phase IIb clinical trial for its CF-101 drug for rheumatoid arthritis. The company today announced that it a trial on the dry capsule of the drug, which found that this delivery method had the same concentration of the drug in the bloodstream as the delivery of the drug in a liquid solution.
Can-Fite expects that the trial will clear the way to repeat the Phase IIb clinical trial for the dry capsule in the hope that removing the solution from the equation will enable it to achieve significant results this time round.
Can-Fite CEO Pnina Fishman said that the trial is due to begin within days, subject to obtaining final approval. The trial will include 230 patients at 30 medical centers.
Can-Fite completed the Phase IIb clinical trial on the solution version of CF-101 in mid-2007. The trial found no significant difference between the drug and the control group along the key drug efficiency measurements. Significant differences were found in secondary measurements.
Can-Fite gave an unusual reason for the results. It claimed that the solvent used for CF-101 and in the placebo given to the control group was effective in treating rheumatoid arthritis, which blurred the differences between the groups.
Published by Globes [online], Israel business news - www.globes-online.com - on February 24, 2008
Market Data 
Markets 
AI
